hallo leute!
ihr könnt mir glauben, dass mich der kursverlauf genauso wie euch maechtig ärgert... aber es gibt news auf der xechem website!!! und zwar folgendes:
Xechem establishes Sickle Cell Advisory Board
NEW BRUNSWICK, NJ – July 11, 2005 − Xechem International, Inc. (OTC BB: XKEM) Board of Directors today announced the establishment and charter membership of its Sickle Cell Research, Efficacy, Awareness and Marketing Advisory Board (the “Advisory Board”), which will assist Xechem’s management in creating public awareness of Xechem’s efforts to bring an effective treatment for Sickle Cell Disease to market in the United States and globally. The Advisory Board consists of distinguished individuals from the fields of pharmaceutical sales and marketing, urban marketing, international consulting, professional networking, entertainment, academia and business.
Members of the Advisory Board, identified below, may be asked from time to time to review and comment on Xechem’s business and marketing strategies with respect to obtaining approval from the United States Food and Drug Administration (US-FDA) for, and the commercial launch of, NIPRISAN (NICOSAN™) under the trade name HEMOXIN™ for the treatment of Sickle Cell Disease in the United States. The Advisory Board will function solely as an advisory body and does not have any legal oversight responsibilities with respect to Xechem or any legal authority to act on Xechem’s behalf. The names and brief biographical profiles of the charter members are set forth below.
VINCENT A. CARTER is an experienced pharmaceutical industry professional involved in the healthcare industry over the last nineteen (19) years. In 2004, Mr. Carter joined MedImmune, Inc., which manufactures a monoclonal antibody used in premature babies. Mr. Carter is an active member of the Healthcare Committee for One Hundred Black Men of New York.
DESIREE V. DELGADO is President and Chief Executive Officer of R2Network.net, Ltd. A DelzBrük Company, a general market media company offering a full-range of services to support the advertising, marketing and public relations process.
DR. GEORGE C. FRASER is Chairman and CEO of FraserNet, Inc., headquartered in Cleveland, Ohio, which is the publisher of the award-winning SuccessGuide Worldwide; The Networking Guide to Black Resources, which is published annually. Dr. Fraser is the author of two books, the critically acclaimed best sellers Success Runs In Our Race: The Complete Guide to Effective Networking in the African American Community and Race for Success: The Ten Best Business Opportunities for Blacks in America. Dr. Fraser spent seventeen (17) years in management with Procter & Gamble, United Way, and Ford Motor Company.
DR. GLENDA BASKIN GLOVER is the Dean of the School of Business at Jackson State University in Jackson, Mississippi. She is a Certified Public Accountant, an attorney and a higher education administrator. She holds a Ph.D. in economics and finance, and is one of two African American women to hold the economics Ph.D-CPA-JD combination in the nation.
DR. MARCELLUS GRACE has served as Professor of Pharmacy Administration and as the Associate Dean of the School of Pharmacy in the College of Pharmacy, Nursing and Allied Health Sciences at Howard University in Washington, DC since July 2004. He previously served as Dean and Professor of Pharmacy Administration in the College of Pharmacy at Xavier University of Louisiana in New Orleans, LA.
NADINE B. HACK is the Founder and President of beCause Global Consulting, Inc., which is a global consulting firm that conceives, develops, facilitates and executes the cause-related strategies and initiatives of corporate and nonprofit clients to build awareness of and support for humanitarian efforts. Ms. Hack has extensive experience with the United Nations, where she served as New York City Commissioner for the United Nations, Consular Corps and International Business, the city’s senior official liaison with the world’s largest diplomatic and business communities. The Boards on which she currently serves include the Desmond Tutu Peace Foundation (President), Africa-America Institute (Vice Chair), World Policy Institute, International League for Human Rights, and Synergos Institute. She has Master Degrees from the John F. Kennedy School of Government at Harvard University (MPA) and the Graduate Faculty of Political and Social Science at New School University (MALS).
J. WAYMAN HENRY III has over ten (10) years of experience in financial analysis, contract negotiations and marketing. He is Co-Founder and Vice President of Business Development of E-Merge International in Atlanta, GA, where he oversees all of the firm’s business operations in sports marketing, entertainment representation, National Football League apparel, event planning and intellectual property development.
WALLYE INESE HOLLOWAY is a Vice President and Account Group Supervisor of Cline Davis & Mann, a leading and award winning pharmaceutical marketing, brand development and advertising agency in New York City, where she has managed marketing and brand development strategies for large pharmaceutical companies, including Pfizer and Amgen since June 2002. Prior to joining Cline, Davis & Mann, Ms. Holloway worked in similar leadership capacities over a period of seven (7) years in New York City with several pharmaceutical marketing and brand management firms, including KPR, Sandler Science, Lowe McAdams Healthcare, and FCB Healthcare.
DR. STEPHEN H. KOLISON, JR. is the Dean and Research Director of the Institute of Agricultural and Environmental Research at Tennessee State University in Nashville, TN. His international experiences include research conducted in the Republic of Trinidad and Tobago, Jamaica, and Ghana, and other professional activities carried out in Belgium, Brazil, Finland, and The Netherlands. Dr. Kolison, Jr. obtained his Ph.D. and M.S. degrees in Forest Economics from Iowa State University of Science and Technology and his B.Sc. degree in General Forestry from the University of Liberia. In November 2004, Dr. Kolison assumed the role of Chair and Chief Executive Officer of the Association of Research Directors, Inc.
DR. KOFI LOMOTEY is a Senior Fellow at the American Association of State Colleges and Universities. He is the former President of Fort Valley State University in Fort Valley, GA. He was previously at Medgar Evers College of The City University of New York, where he was the Senior Vice President and Provost. Dr. Lomotey is the editor, co-editor or author of seven books and has published numerous articles and book chapters. Dr. Lomotey holds a B.A. degree from Oberlin College in Economics, a M.Ed. degree from Cleveland State University in Elementary Curriculum, and obtained his M.A. and Ph.D. degrees from Stanford University.
DR. TAMARA NEW is the Director of the Comprehensive Sickle Cell Center at Harlem Hospital Center in New York, NY. Dr. New also holds other leadership positions at Harlem Hospital Center, including Director of the Pediatric Residency Program, Director of the Pediatric Hematology-Oncology of Harlem Hospital Center and Clinical Director of the third year medical student Pediatric Clerkship program. Dr. New obtained her Doctor of Medicine degree from Mount Sinai School of Medicine, New York, NY and her BA in Chemistry from Smith College, Northhampton, MA.
DAKOTA PIPPINS is the Founder and CEO of Pippins Strategies, LLC, a marketing consulting firm that advises large corporations on strategies for attracting Urban consumers. Mr. Pippins is an Adjunct Assistant Professor at New York University where he previously served for five years as Director of NYU’s Management Institute and currently teaches a course on Urban Marketing Strategies. Mr. Pippins also serves on the Board of Directors of Hormel Foods Corp.
DR. MARCY STREET is the owner of Doctor’s Approach Dermatology & Laser Center in Lansing, MI, and is a Member of the Michigan Board of Medicine & Disciplinary Committee. Dr. Street has been in private practice since 1991 as a Medical Dermatologist, Skin Cancer Specialist and Mohs Surgeon with a CLIA approved Mohs surgery laboratory. Dr. Street is also a Clinical Instructor in Michigan State University’s Department of Internal Medicine, where she has lectured to medical students and residents on topics in general and surgical dermatology since 1991. Dr. Street received her M.D. from the University of Illinois College of Medicine in Chicago, IL.
Dr. Ramesh C Pandey, Chairman and CEO of Xechem said “we are very fortunate to have attracted such a knowledgeable and prestigious group of distinguished professionals and business leaders to help us in marketing NICOSAN™/HEMOXIN™ for the treatment of Sickle Cell Disease. We welcome the new Advisory Board members and are looking forward to the valued assistance we know they will offer us in bringing this extremely important drug into the hands of the millions of people who are suffering from this terrible disease.”
About Xechem
Xechem is a development stage biopharmaceutical company engaged in the research development and production of niche generic and proprietary drugs from natural sources. Its principal product under development is NICOSAN™/HEMOXIN™, which has shown efficacy in the treatment of Sickle Cell Disease, according to Xechem’s public filings. Xechem is headquartered in New Brunswick, New Jersey.
For further information, contact the Company or Stephen Burg at 707-425-8855.
This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties
|
Thread abonnieren
